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Review Article
Prevalence of multimorbidity in community
settings: A systematic review and
meta-analysis of observational studies
Hai Nguyen , Gergana Manolova, Christina Daskalopoulou,
Silia Vitoratou, Martin Prince and A Matthew Prina
Abstract
Background: With ageing world populations, multimorbidity (presence of two or more chronic diseases in the same
individual) becomes a major concern in public health. Although multimorbidity is associated with age, its prevalence varies.
This systematic review aimed to summarise and meta-analyse the prevalence of multimorbidity in high, low- and middle-
income countries (HICs and LMICs).
Methods: Studies were identified by searching electronic databases (Medline, Embase, PsycINFO, Global Health, Web of
Science and Cochrane Library). The term ‘multimorbidity’ and its various spellings were used, alongside ‘prevalence’ or
‘epidemiology’. Quality assessment employed the Newcastle-Ottawa scale. Overall and stratified analyses according to
multimorbidity operational definitions, HICs/LMICs status, gender and age were performed. A random-effects model for
meta-analysis was used.
Results: Seventy community-based studies (conducted in 18 HICs and 31 LMICs) were included in the final sample.
Sample sizes ranged from 264 to 162,464. The overall pooled prevalence of multimorbidity was 33.1% (95% confidence
interval (CI): 30.0–36.3%). There was a considerable difference in the pooled estimates between HICs and LMICs, with
prevalence being 37.9% (95% CI: 32.5–43.4%) and 29.7% (26.4–33.0%), respectively. Heterogeneity across studies was
high for both overall and stratified analyses (I2 > 99%). A sensitivity analysis showed that none of the reviewed studies
skewed the overall pooled estimates.
Conclusion: A large proportion of the global population, especially those aged 65þ, is affected by multimorbidity. To
allow accurate estimations of disease burden, and effective disease management and resources distribution, a standardised
operationalisation of multimorbidity is needed.
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Introduction
As the world’s populations are ageing rapidly, multimor-
bidity is becoming a major concern in public health.
According to a recent report by the Academy of Medical
Science,1 in most high-income countries (HICs), multimor-
bidity is considered the norm, not the exception. Multimor-
bidity also appears to be increasingly prevalent in low- and
middle-income countries (LMICs).1 Patients experiencing
multiple chronic conditions often have poorer health
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outcomes, such as declined physical and mental health
functioning,2 higher mortality rates3 and frailty.4 Their
needs for medical care are also different. Instead of a highly
specialised but isolated approach, as used for single disease
treatment, multimorbidity patients need a complex and
structured care plan.1,5 This has serious impact on disease
management, healthcare utilisation and costs.6–8 To assess
the impact of multimorbidity on public health and to proj-
ect medical care needs for patients with multimorbidity, an
accurate estimation of its prevalence is critical. Yet, the
complex nature of multimorbidity poses great difficulties
for research into this topic area. This is due partly to incon-
sistencies in the conceptualisation and definition of multi-
morbidity. For instance, despite being distinct clinical
entities, multimorbidity and comorbidity are still used
interchangeably. While the former is defined as the co-
occurrence of two or more chronic diseases, the latter is
perceived as ‘the occurrence of medical conditions addi-
tional to an index disease’.9 The ambiguity in the concep-
tualisation of multimorbidity leads to a lack of a consensus
about its operationalisation. The number of diseases used as
cut-off points, disease combination and measure of multi-
morbidity vary across studies.
Although multimorbidity prevalence and its variations
have been examined and summarised in a number of sys-
tematic reviews,10,11 these reviews usually only included
studies in HICs. Only one review synthesised evidence on
the prevalence and outcomes of multimorbidity in South
Asia.12 Nonetheless, there has not been a review that sys-
tematically assessed the variations of multimorbidity pre-
valence estimates at a global level. Our aims were therefore
to (1) summarise the available evidence in the literature on
the global prevalence of multimorbidity in the context of
community settings, (2) carry out a meta-analysis of the
prevalence estimates to provide a pooled estimate and (3)
assess how multimorbidity was operationalised across the
different studies to examine whether this factor could
explain the heterogeneity of the prevalence estimates.
Methods
We conducted a systematic review and meta-analysis (reg-
istered on PROSPERO Ref no. CRD42018087435), which
followed the PRISMA statement for systematic review and
analysis13 (Online Supplement 1).
Inclusion and exclusion criteria
Eligible studies were original, peer-reviewed articles (pub-
lished either online or as hard copy, with available abstracts
in English). Opinion pieces, conference presentations,
books, letters, editorials, dissertations/theses or abstracts
were not included. Studies with an index disease (e.g. mul-
timorbidity among HIV-infected individuals) were also not
eligible for inclusion, because they were deemed comor-
bidity studies. Only studies that clearly stated that their
participants were community-based adults were consid-
ered. In other words, studies that recruited participants
from communal establishments, such as hospitals, hos-
pices, nursing homes or prisons, were ineligible. Those that
used solely medical records from general practice as data
source were also excluded to avoid selection bias. The
study designs were restricted to cross-sectional and long-
itudinal studies. Where the design was longitudinal, only
prevalence at baseline was included. Case-control and
interventional studies (such as randomised controlled
trials) were removed from consideration. There were no
further restrictions regarding demographic characteristics
of the population under study, for instance, age, sex, or
socioeconomic status. Since the outcome of interest was
the prevalence of multimorbidity, only studies that reported
on this were selected.
Search strategy and study selection
We conducted an online literature search on Medline (Ovid
interface), Embase (Ovid interface), PsycINFO (Ovid inter-
face), Global Health (Ovid interface), Web of Science and
Cochrane Library electronic databases, from inception up
to May 2019. The term ‘multimorbidity’ and its various
spellings (e.g. ‘multi-morbidity’, ‘multimorbidities’,
‘multi-morbidities’, ‘multi morbidity’, ‘multi morbidities’,
‘multiple morbidities’, ‘multiple-morbidities’) and ‘preva-
lence’ or ‘epidemiology’ were used (Online Supplement 2).
We were interested in how multimorbidity was defined so
deliberately excluded ‘comorbidity’ and other synonyms in
our search strategy.
The titles and abstracts of all hits returned by the search
were screened initially by the first reviewer (HN). The
second reviewer (CD) tested a 10% random sample of all
references to ensure that eligible studies were not missed
out. Studies that satisfied all the eligibility criteria specified
above were kept for full-text screening. The full-text
screening was done independently by two reviewers (HN
and GM). Where there were disagreements, HN and GM
discussed to resolve them. AMP was consulted when agree-
ment could not be reached. Disagreements were finally
resolved by consensus.
Data extraction and quality assessment
We extracted all potentially eligible studies to EndNote
(EndNote X8, Thomson Reuters). Duplicate articles were
removed using EndNote X8 auto-deduplication function.
Those that were not detected by this function were removed
manually during the first screening.
A data extraction sheet was developed, pilot-tested on
five randomly selected eligible studies and refined accord-
ingly. We extracted the following information: year of
study, study design, country of study, data source, sample
size, mean age (men/women), definition of multimorbidity,
measure of multimorbidity, prevalence of multimorbidity,
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number of diseases, ascertainment of diseases and combi-
nation of diseases. In case this information could not be
retrieved from the included studies, the corresponding
authors of such studies were contacted. Six authors were
contacted and three provided the requested information.
We adopted the age-related adjustmentmethod developed
by Fortin et al11 to enable comparisons of age-specific pre-
valence across studies. If prevalence was reported for an age
range, we calculated mean age between the lower and upper
limits to present that range.11 If prevalence was reported for
an age range with an upper or lower limit only, we adjusted
the age to 10 years above the lower limit and 10 years below
the upper limit.11 Exception of this rule was when the pre-
valence was reported for age groups such as 65þ or 75þ, we
used this prevalence without making any age adjustments.
To assess the risk of bias for individual studies, the
Newcastle-Ottawa Scale (NOS) for assessing the quality
of non-randomised studies was used. NOS uses eight items,
categorised into three domains of potential bias, namely
selection (representativeness of the sample, sample size,
non-respondents, ascertainment of the exposure), compar-
ability (the subjects in different outcome groups are com-
parable, based on the study design or analysis; and
confounding factors are controlled) and outcome (assess-
ment of outcome and statistical test).14 A study can be
given a maximum of one star for each item within the
selection and outcome categories. A maximum of two stars
can be given for comparability. Thresholds for converting
the NOS to Agency for Healthcare Research and Quality
standards (good, fair and poor)15 are as follows:
 Good quality: 3 or 4 stars in selection domain AND
1 or 2 stars in comparability domain AND 2 or 3
stars in outcome/exposure domain
 Fair quality: 2 stars in selection domain AND 1 or 2
stars in comparability domain AND 2 or 3 stars in
outcome/exposure domain
 Poor quality: 0 or 1 star in selection domain OR 0
star in comparability domain OR 0 or 1 star in out-
come/exposure domain.
Eligible studies after full-text screening were assessed
(Online Supplement 3). Both good and poor quality studies
were retained for sensitivity analysis at a later stage.
Data analysis
Overall and stratified analyses according to multimorbidity
operational definitions (2þ and 3þ diseases cut-off points)
and HIC–LMIC status were performed. HICs and LMICs
were determined using the World Bank classification list of
economies.16 Where possible, prevalence of multimorbid-
ity was also stratified by age and gender. Studies that
reported multimorbidity prevalence, both standardised and
non-standardised, using the 2þ chronic diseases cut-off
point as definition, were included in the meta-analysis.
To perform the meta-analysis, we used the metaprop com-
mand.17 Multimorbidity prevalence was calculated as the
quotient of the number of people with multimorbidity
(numerator) and sample size (denominator). Where not
available, the numerator was converted from the percent-
age of people with multimorbidity. Using absolute numbers
to generate prevalence estimates enabled the calculation of
standard error. Heterogeneity across studies was evaluated
using I2 statistic.18 It was expected that the I2 statistic
would be high, due to the heterogeneous operationalisation
of multimorbidity. Hence, a random-effects model was
used. Finally, a sensitivity analysis was carried out to test
the influence of a single study in meta-analysis estimation
of the pooled prevalence. All quantitative synthesis of this
review was done in STATA version 15.19
Results
Overview of studies
We identified 4360 studies from the initial search. After
removing duplicates and records that were not original arti-
cles, there were 274 studies eligible for full-text screening.
Two hundred four studies were further excluded after full-
text screening, leaving 70 for final qualitative and quanti-
tative synthesis. The PRISMA flow diagram in Figure 1
shows the exact process of studies selection.
Study quality and characteristics
Based on the NOS data quality assessment system, 63 stud-
ies were rated good quality (with a score of 6 or 7), 2
studies were rated fair quality (with a score of 5) and 5
studies were rated poor quality (with a score of 2 or 4).
Those deemed poor quality were so because they omitted
information about the representativeness of their data, sam-
pling strategy or response rates (see Online Supplement 3).
The total number of participants across 70 studies was
1,180,111 (men: 47.5%, women: 52.5%), with sample size
ranging from 264 to 162,464. The mean age varied between
36 years and 75 years old. Thirty-seven studies were con-
ducted in HICs (5 in Australia,20–24 4 in Canada,25–28 4 in
Spain,29–32 3 in Germany,33–35 3 in Portugal,36–38 3 in
the United Kingdom,39–41 3 in Hong Kong,42–44 2 in Sin-
gapore,45,46 2 in the United States47,48 and 1 each in
Cyprus,49 Czech Republic,29 Denmark,50 Estonia,29 Fin-
land,30 France,51 Hungary,29 Latvia,29 Poland,30 Ireland,52
South Korea,53 the Netherlands,54 Sweden55 and Switzer-
land56) and 35 in LMICs (9 in China,30,57–64 8 in
India,30,65–71 10 in Brazil,29,72–80 3 in South Africa,29,30,81
2 in Ghana,29,30 2 in Pakistan,29,71 2 in Bangladesh,29,82 2 in
Burkina Faso,29,83 and 1 each in Bosnia and Herzegovina,29
Colombia,84 Dominican Republic,29 Egypt,85 Georgia,29
Iran,86 Kazakhstan,29 Kenya,29 Kosovo,87 Laos,29 Malaysia,29
Mauritius,29 Mexico,30 Morocco,29 Myanmar,29 Namibia,29
Nepal,29 Paraguay,29 the Philippines,29 Russia,30 Serbia,88 Sri
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Lanka,29 Ukraine,29 Uruguay29 and Vietnam89) over a period
of 25 years, from1992 to 2017.Most of them (63 studies)were
cross-sectional design, and seven21,23,39,43,54,57,60 had a long-
itudinal design, from which we used data from the baseline
assessment. Only 5 out of 7022,47,75,76,80 studies focused solely
on subgroups of eithermen orwomen. The number of diseases
included in eligible studies ranged from4 to 40 (with hyperten-
sion, diabetes, arthritis and stroke being four most frequent
conditions). Disease count was the most common measure of
multimorbidity, based on self-reported data. Details of studies’
characteristics are provided in Table 1.
Prevalence of multimorbidity
Among 37 nationally representative studies in HICs, one
conducted in Hong Kong reported the lowest prevalence
(3.5%)43 while another conducted in Russia reported the
highest prevalence (70%).30 Of those that were con-
ducted in LMICs, one study which used data from a
household survey in 26 villages in India reported the
lowest multimorbidity prevalence (1%).68 Another study
with data derived from the Confucius Hometown Project
in China, on the contrary, reported the highest preva-
lence estimate (90%).64
In addition to the common cut-off point of 2þ chronic
diseases (2þMM) used in 68 studies, 20 studies also inves-
tigated the prevalence estimate when multimorbidity was
defined as ‘the co-occurrence of three or more chronic
diseases’. As the number of diseases included in the defi-
nition increased, the prevalence decreased (Table 2). The
biggest difference was observed in Khanam et al.’s study,82
where the prevalence of 3þ morbidities (3þMM) was
Figure 1. PRISMA flow diagram of studies selection.
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Table 1. Characteristics of included studies.a
Study
(country of study)
Data
collection
period Data source
Sample
size Age
Gender
(% men)
Prevalence (%)
(95% CI)
Afshar 2015
(28 countries)
2003 WHO World Health Survey 125404 18þ 48.5 7.8 (6.5–9.1)
Agborsangaya
2013 (Canada)
2012 Health Quality Council of Alberta
(HQCA) 2012 Patient Experience
Survey
4803 18þ 44.2 36.1 (34.7–37.3)
Alaba 2013
(South Africa)
2008 South Africa National Income
Dynamic Survey (SA-NIDS)
11638 18þ 39.0 4.0 (3.6–4.4)
Alimohammadian 2018
(Iran)
2004–2008 Golestan Cohort Study (GCS) 49946 40–75 42.4 19.4 (19.1–19.8)
Amaral 2018 (Brazil) 2010 Population-based study 264 60–102 39.0 66.3 (60.4–71.7)
Araujo 2018 (Brazil) 2015 Population-based study 4001 60þ 47.2 29.0 (27.6–30.5)
Banjare 2014 (India) 2011–2012 Cross-sectional survey 310 60þ 49.4 56.8 (51.2–62.2)
Buttery 2016
(Germany)
1997–1999 German National Health Interview
and Examination Survey 1998
(GNHIES98)
2884 50–79 47.6 M: 36.1 (33.6–38.7)
F: 40.5 (38.1–43.0)
Camargo-Casas 2018
(Colombia)
2012 The SABE-B study 2000 60þ 36.6 40.4 (38.3–42.6)
Chen 2018 (China) 2011 China Health and Retirement
Longitudinal Study (CHARLS)
3737 45þ 51.9 45.5 (41.4–49.7)
Cheung 2018
(Hong Kong)
2016–2017 Jockey Club Community eHealth
Care project
2618 60þ 47.5 41.8 (39.9–43.7)
de Carvalho 2017
(Brazil)
2013 National Health Survey 60202 18þ N/A 23.6 (22.9–24.3)
de Souza Santos
Machado2012(Brazil)
2005 Population-based study 377 40–65 Women
only
39.3 (34.5–44.3)
de Souza Santos
Machado2013(Brazil)
2011 Population-based study 622 50þ Women
only
58.2 (54.3–62.0)
Dhawalni 2016
(England)
2002–2003 English Longitudinal Study of Ageing
(ELSA)
11212 50þ 46.4 31.7 (30.9–32.6)
El Lawindi 2019 (Egypt) 2016–2017 Community-based study 2317 18–85 54.9 19.6 (18.0–21.3)
Fuchs 2012 (Germany) 2008–2009 German Health Update (GEDA) 21262 18–100 48.5 M: 36.3 (35.4–37.2)
F: 43.9 (43.0–44.8)
Garin 2016 (9 countries) 2008–2012 WHO study on Global AGEing and
Adult Health (SAGE) and the
Collaborative Research on Ageing
in Europe (COURAGE) survey
41909 50þ 46.5 62.7 (55.2–70.1)
Ge 2018 (Singapore) 2015–2016 The Population Health Index Survey 1940 21þ 44.3 36.9 (34.7–39.0)
Gu 2017 (China) 2013 Cluster random sampling survey 2452 60–93 51.5 49.4 (47.4–51.4)
Hameed 2015 (India) 2013 Community-based study 375 60þ 57.9 79.4 (75.1–83.3)
Hien 2014
(Burkina Farso)
2012 Cluster random sampling survey 389 60þ 55.3 65.0 (59.9–69.4)
Humphreys 2018 (UK) 2007–2008 The Hertfordshire Cohort study 2299 64–68 51.0 43.4 (41.4–45.5)
Islam 2014 (Australia) 2009 Stratified random sampling survey 4574 50þ N/A 52.0 (50.5–53.4)
Jankovic 2018 (Serbia) 2013 2013 Serbian National Health Survey 13765 20þ 46.0 30.2 (29.4–30.9)
Jerliu 2013 (Kosovo) 2011 Nationwide cross-sectional study 1890 65þ 50.2 51.1 (48.8–53.3)
Johnston 2019 (UK) 2001 The Aberdeen Children of the 1950s
(ACONF)
7184 50þ 47.7 5.4 (4.9–6.0)
(continued)
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Table 1. (continued)
Study
(country of study)
Data
collection
period Data source
Sample
size Age
Gender
(% men)
Prevalence (%)
(95% CI)
Khanam 2011
(Bangladesh)
2003–2004 Poverty and Health in Ageing study 452 60–92 45.1 53.7 (49.2–58.3)
Kiliari 2014 (Cyprus) 2008 Nationally based survey 465 N/A 43.2 28.5 (24.7–32.9)
Kirchberger 2012
(Germany)
2008–2009 KORA-AGE study 4127 65–94 48.8 58.6 (50.7–60.2)
Kshipra 2018 (India) 2012–2013 Cross-sectional study 400 50þ N/A 31.0 (26.7–35.7)
Kumar 2015 (India) 2012–2013 Household survey 55091 N/A 52.3 0.7 (0.6–0.7)
Lai 2019 (Hong Kong) 1999 Thematic Household Survey (THS) 17229 35þ 49.5 3.5 (3.2–3.8)
Laires 2019 (Portugal) 2014 The Portuguese National Health
Interview Survey (Inquerito
Nacional de Saude, INS)
15196 25–79 44.0 43.9 (43.1–44.7)
Lalitha 2016 (India) 2009 Household survey 815 40þ 51.3 44.1 (40.6–47.5)
Lang 2015 (US) 2012–2013 EuroQol 5 dimensions (EQ-5D)
study
3058 40–64 Women
only
30.6 (29.0–32.3)
Larsen 2017 (Denmark) 2013 Danish National Health Survey 162283 16þ 49.0 39.7 (39.4–39.9)
LeCossec 2016 (France) 2008 Disability Healthcare Household
Section Survey (HSM – Enquete
Handicap Sante - Menages)
11089 55þ 45.1 M: 18.7 (17.6–19.9)
F: 15.2 (14.3–16.1)
Li 2019 (China) 2017 Community-based survey 4833 60þ 45.5 16.1 (15.1–17.1)
Loprinzi 2015 (US) 2005–2006 2005–2006 National Health and
Nutrition Examination Survey
(NHANES)
2048 20þ 50.9 58.4 (55.3–61.5)
Loza 2009 (Spain) 1999–2000 EPISER study 2192 N/A N/A 30.0 (25.0–34.0)
Lujic 2017 (Australia) 2005–2009 45 and up study 90352 45þ 44.3 37.4 (37.1–37.7)
Maregoni 2016
(Sweden)
2001–2004 SwedishNational Study onAgeing and
Care in Kungsholmen (SNAC-K)
3155 60þ 35.7 52.4 (50.6–54.2)
Mini 2017 (India) 2011 UNFPA funded national survey 9852 60þ 47.0 30.7 (29.8–31.6)
Ninh 2015 (Vietnam) 2010 Population-based study 2400 60þ 34.8 41.6 (39.5–43.8)
Noguchi 2016
(Australia)
2005–2007 Concord Health and Ageing in Men
Project (CHAMP)
1705 70–99 100.0 69.3 (67.1–71.5)
Nunes 2016 (Brazil) 2012 Population-based cross-sectional
study
2927 20þ 41.1 29.1 (27.1–31.1)
Nunes 2019 (Brazil) 2015–2016 The Brazilian Longitudinal Study of
Ageing (ELSI-Brazil)
9412 50þ 46.0 67.8 (65.6–69.9)
Nunes 2015 (Brazil) 2008 Population-based survey 1593 60þ 37.2 81.3 (79.3–83.3)
Pache 2015
(Switzerland)
2003–2006 Cohorte Lausannoise (CoLaus)
study
3714 35–75 47.0 34.8 (33.3–36.4)
Park 2018 (Korea) 2013–2014 The sixth Korean National Health
and Nutritional Examination
Survey (KNHANES)
5996 50þ 46.6 26.8 (25.7–27.9)
Picco 2016 (Singapore) 2012–2013 Well-being of the Singapore Elderly
(WiSE) study
2565 50þ N/A 55.4 (53.4–57.3)
Ramond-Roquin 2016
(Canada)
2010 PRECISE study 1710 18þ 48.3 63.8 (61.5–6.1)
Roberts 2015 (Canada) 2011–2012 Canadian Community Health Survey
(CCHS)
105416 25–75 40.5 12.9 (12.6–13.2)
Rodrigues 2018
(Portugal)
2013–2015 EpiDoc 2 study 2393 65þ 44.2 67.9 (66.0–9.7)
(continued)
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reported to be 19.5%, which represented a decrease of 34.3
percentage points compared to the prevalence of 2þ mor-
bidities (53.8%). On average, the weighted difference
between the prevalence of 2þMM and 3þMM was 12.9
percentage points.
Among 25 studies that explored gender variations, the
majority (21 studies) reported a higher prevalence in women
than in men. Alaba and Chola,81 in particular, found that
multimorbidity was almost double in females (74% in
females vs. 26% in males). The reverse trend was observed
in only four studies.51,65,67,68 Nevertheless, when men were
reported to have higher multimorbidity prevalence, the dif-
ferences in prevalence estimates between the two sexes were
relatively small (Online Supplement 4). Figure 2 shows that
the prevalence of multimorbidity invariably increased for
both men and women as they aged. There was an upward
trend, where multimorbidity prevalence was positively asso-
ciated with age. Of nine studies that reported age–sex spe-
cific prevalence, Kirchberger et al.35 found that the highest
prevalence was in the 85þ group (men: 76.3%; women:
88.1%). Although this association was supported by 24 other
studies that investigated age-specific prevalence, three stud-
ies observed a lower prevalence estimate among the oldest
old (80–85 age group). Kiliari et al,49 in particular, found
that after the age of 85, the prevalence of multimorbidity in
Cyprus decreased to 33.3% (from 80% in the previous age
bracket). The highest prevalence estimate was reported for
the 75þ age group in Spain (92.9%).32 The largest variation,
with prevalence of multimorbidity ranging from 16.3% to
87.5%, was around the age of 70.
Table 1. (continued)
Study
(country of study)
Data
collection
period Data source
Sample
size Age
Gender
(% men)
Prevalence (%)
(95% CI)
Romana 2019 (Portugal) 2015 Inquerito Nacional de Saude com
Exame Fisico (INSEF)
4911 25–74 47.5 38.4 (37.0–39.8)
Ruel 2014 (Australia) 2000–2002 North West Adelaide longitudinal
Health Study (NWAHS)
1854 20þ 44.1 32.0 (30.0–4.0)
Ruel 2014 (China) 2002 Jiangsu longitudinal Nutrition Study
(JIN)
1020 18þ 48.0 14.0 (12.0–16.3)
Ryan 2018 (Ireland) 2010 The Irish Longitudinal Study on
Ageing (TILDA)
4823 50þ N/A 53.7 (52.3–55.1)
Sakib 2019 (Canada) 2015 The Canadian Longitudinal Study of
Ageing (CLSA)
29841 45–64 49.4 39.6 (38.4–40.7)
Singh 2019 (India
and Pakistan)
2010–2011 The Cardiometabolic Risk Reduction
in South Asia Surveillance Study
(CARRS Surveillance Study)
16287 20þ 47.3 9.4 (8.7–10.1)
Su 2016 (China) 2013 Multistage cluster study 2058 80þ 42.1 49.2 (47.0–51.3)
Timmermans 2019 (the
Netherlands)
1992–1993 The Longitudinal Ageing Study
Amsterdam (LASA)
2199 64–84 44.9 43.6 (41.6–45.7)
Valadares 2015 (Brazil) 2012–2013 Cross-sectional study 736 45–60 Women
only
53.0 (49.4–56.6)
Violan 2013 (Spain) 2006 Health Survey for Catalonia database
2006
15926 15þ 49.5 59.6 (58.8–60.4)
Wang 2014 (China) 2011 Cross-sectional community
household survey
162464 All 51.4 11.1 (10.6–11.6)
Wang 2017 (Australia) 2007 2007 Australian National Survey of
Mental Health and Wellbeing
8841 16–85 49.7 28.7 (27.8–9.7)
Wang 2015 (China) 2010–2011 Confucious Hometown Aging
Project (CHAP)
1480 60þ 40.6 90.5 (88.9–91.9)
Wang 2015 (China) 2012 Jilin Provincial chronic Disease
Survey
21435 18–79 N/A 24.7 (24.1–25.4)
Wong 2008 (Hong
Kong, China)
N/A Cross-sectional study 3394 65þ 56.0 68.0 (66.4–9.5)
M: male; F: female; CI: confidence interval.
aMultimorbidity was defined as the presence of two or more chronic diseases in the same individual; 95% CI as reported in original studies was presented
in Table 1. Where this was not available, we used the 95% CI generated by STATA for the meta-analysis. For studies that investigated multimorbidity
prevalence in several countries, the prevalence presented in Table 1 was the pooled country prevalence estimates.
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Meta-analysis
Data combined from 106 prevalence estimates (from 68
studies) showed that the overall random-effect pooled
prevalence of multimorbidity was 33.1% (95% CI):
30.0–36.3%). There was a considerable difference in the
pooled prevalence estimates between HICs (44 estimates)
and LMICs (62 estimates). Specifically, the pooled preva-
lence of multimorbidity among HICs was 37.9% (95%
CI: 32.5–43.4%), while the pooled prevalence estimate
among LMICs was 29.7% (26.4–33.0%; Figures 3(a) and
(b), Online Supplement 5).
However, when standardised prevalence was removed
(34 estimates), LMICs’ prevalence was found to be higher
than that of HICs. This difference, nonetheless, was mar-
ginal, with HICs prevalence being 41.3% (95% CI: 35.2–
47.4%) and LMICs 43.5% (95% CI: 38.4–48.6%). The
overall pooled estimate of non-standardised prevalence
rose to 42.4% (95% CI: 38.1–46.6%; Online Supplement
6). Heterogeneity across studies, both before and after
adjusting for standardisation, was very high (I2 > 99%).
A sensitivity analysis showed that none of the studies
included in our review skewed the overall pooled estimates.
Discussion
This systematic review provides an up-to-date and compre-
hensive analysis of multimorbidity prevalence at a global
level. It shows that prevalence estimates varied substan-
tially according to age, gender and operational definitions
of multimorbidity. This was due to wide variations in
sample size, characteristics and how prevalence was
reported across studies. Nevertheless, the main findings
from our review were consistent with those in previous
studies and systematic reviews.10,90 Specifically, our data
suggested that multimorbidity increases with age. While
the prevalence estimates varied between and within age
groups, most studies in our sample indicated that a large
proportion (more than 50% in many cases) of individuals
over the age of 65 had multimorbidity. Where prevalence
estimates by gender were reported, females appeared to
have higher multimorbidity prevalence rates than males.
This is indicative of an association between sex and multi-
morbidity (evidence of which was provided in multiple
studies74,86). Although there was no uniformity in disease
combinations and cut-off points, it followed that the higher
the cut-off point, the lower the prevalence. This finding
supported an observation by Harrison et al.,91 where it was
found that from 44% (when multimorbidity was defined as
2þ diseases), the prevalence reduced to 27% (for 3þ dis-
eases), 15% (for 4þ diseases), 7% (for 5þ diseases) and
only 3% (for 6þ diseases). The highest prevalence esti-
mates in our sample were reported in studies that used the
2þMMdefinition. Harrison et al.91 also ascertained that the
combination of diseases may make multimorbidity preva-
lence differ significantly. In the existing literature, a range
of different combinations have been proposed from a list of
16 chronic diseases92 to a list of 291 diseases93 and any-
thing in between.94 Ferrer et al.92 argued that an open list of
diagnoses should be used, since it gave the highest preva-
lence estimate. In our sample, the number of diseases
Table 2. Prevalence of multimorbidity by two or more diseases and three or more diseases cut-off points.
Study 2þ MM (%) 3þ MM (%) Difference Sample size
Araujo (2018) 29.0 15.2 13.8 4001
Banjare and Pradhan (2016) 56.8 30.0 26.8 310
Dhawalni (2016) 31.7 11.7 20.0 11212
Garin (2014) 9.7 5.4 4.3 4583
Humphreys (2018) 47.6 21.6 26.0 2299
Khanam (2011) 53.8 19.5 34.3 452
Lang (2015) 17.9 12.7 5.2 3058
Lujic (2017) 37.4 8.7 28.7 90352
Nunes (2016) 29.1 14.3 14.8 2927
Nunes (2019) 67.8 47.1 20.7 9412
Nunes (2015) 81.3 64.0 17.3 1593
Ramond-Roquin (2016) 63.8 48.9 14.9 1710
Roberts (2015) 12.9 3.9 9.0 105416
Ruel (2014) 32.0 9.0 23.0 1854
Su (2016) 49.2 18.5 30.7 2058
Wang (2014) 11.1 6.1 5.0 162464
Wang (2015) 90.5 76.5 14.0 1480
Wang (2015) 24.8 12.0 12.8 21430
Wang (2017) 26.0 10.1 15.9 8820
Wong (2008) 68.0 42.4 25.6 3394
Average difference 18.4
Weighted average difference 12.9
2þMM: two or more disease cut-off point; 3þMM: three or more disease cut-off point.
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ranged from 4 to 40, but a similar trend (i.e. the higher the
disease number, the higher the prevalence) was not found.
The prevalence of multimorbidity estimated using a list of
40 diseases was, in fact, lower than the prevalence esti-
mated using a list of six diseases. The concern perhaps
should be shifted to the fact that there were no specific
criteria for disease inclusion in these studies. They were
often determined by the authors’ experience and expertise
rather than a standardised list. Most commonly, conditions
included were those with the highest prevalence or clinical
relevance.12
Our quantitative synthesis of the data generated a
pooled prevalence estimate of 33.1% (95% CI: 30.0–
36.3%), which must be interpreted with some caveats.
When both age–sex standardised and non-standardised
prevalence estimates were included, stratified analysis
suggested that there were differences between HICs and
LMICs multimorbidity prevalence. Specifically, multi-
morbidity prevalence was higher in HICs than LMICs.
However, when only non-standardised prevalence esti-
mates were taken into consideration, the prevalence of
multimorbidity was shown to be marginally higher in
LMICs than in HICs. This reverse trend could be due to
the fact that of the 34 standardised prevalence estimates
removed, 27 of them were from LMICs. The inclusion of
these 27 standardised estimates might have deflated the
original pooled prevalence estimated for LMICs. None-
theless, it was not yet clear whether the geographical var-
iation in multimorbidity prevalence was genuine (i.e.
multimorbidity prevalence was higher in HICs than
LMICs) or whether it simply reflected the differences in
diagnostic and data management systems between HICs
and LMICs. Xu et al.95 suggested that the difference
between HICs and LMICs prevalence estimates might
also be due to the comparatively limited knowledge on
multimorbidity from LMICs compared with HICs, which,
consequently, led to fewer publications on multimorbidity
prevalence in LMICs.95
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Figure 2. Age- and sex-specific prevalence of multimorbidity.
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The reduction in heterogeneity level as a result of stratified
analysis was not considerable (all I2 statistics were greater
than 99%). In this review, attempts have beenmade to ensure
consistency of prevalence estimates by including in themeta-
analysis only studies that used 2þMM definition, disease
count measure and self-reported data in community settings.
Implications of findings
Inconsistencies in the prevalence of multimorbidity may
lead to an over-/underestimation of healthcare costs,
hospital admissions, resources distribution and general dis-
ease burden. This, subsequently, hinders the effects of
health interventions. The need for a uniform method to
estimate multimorbidity prevalence, therefore, becomes
more and more urgent. Future research on multimorbidity
is urged to follow a standardised protocol, using a consis-
tent disease classification system, disease cut-off point and
measure of multimorbidity. Since the age structures of
HICs and LMICs are different, both crude and standardised
prevalence should be reported. Results from prevalence
studies should also be stratified by gender and age. Age
Figure 3. (a) Forest plot showing multimorbidity prevalence in HICs. (b) Forest plot showing multimorbidity prevalence in LMICs.
HIC: high-income country; LMIC: low-income country.
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groups, where possible, should be categorised using stan-
dardised intervals.
Strengths and limitations
The strengths of this review lie in the fact that our study
selection and screening processes were vigorous. Our
search strategy and inclusion criteria were comprehensive,
which, subsequently led to our review being the largest
systematic review on multimorbidity prevalence to date.
Results after the initial screening were double-checked by
a second reviewer, and the full-text screening that followed
was carried out independently. Our data extraction and
quality assessment were also cross-checked and very few
disagreements arose. The studies included in the analysis
were mainly of high quality, all community-based and cov-
ered both HICs and LMICs. This enabled the findings to be
extrapolated to the global population.
This review, however, was not without limitations. Not-
withstanding effort made to ensure eligible studies were
Figure 3. (Continued).
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included, there were still possibilities that potentially eligi-
ble articles (especially those not in English) were missed
out. This might contain studies that focused on two or
more chronic conditions without using the term multimor-
bidity in their titles or abstracts. Most of the studies in our
sample reported multimorbidity prevalence based on self-
reported data (though some also used medical examina-
tions such as blood test). Results of such studies were
therefore prone to response bias (due to misunderstanding
of survey questions or recall timeframe). The majority of
studies in this review were cross-sectional, which only
allowed estimation of multimorbidity at a certain point
in time. In addition, the measures of multimorbidity used
in these studies were mostly disease count, with only one
exception of the functional comorbidity index (FCI) in
one study.56 Disease count and FCI were only 2 of nearly
20 different measures available to date. Fortin et al.96
reported a much higher prevalence of multimorbidity
when using the Cumulative Illness Rating Scale, com-
pared with the prevalence measured by disease count in
other studies.96 A simple count of chronic diseases,
despite being the most common method to estimate multi-
morbidity prevalence, may sometimes be considered too
crude a measure.97 That being said, in a cross-sectional,
population-based study conducted in Switzerland by
Pache et al.,56 the prevalence of multimorbidity measured
by disease count was found to be higher than that mea-
sured by the FCI.56 The lack of consistency in measuring
and reporting the prevalence of multimorbidity in the
included studies was a factor that needs to be taken into
account when interpreting findings from our analyses.
However, as discussed above, given that there is no con-
sensus about multimorbidity, heterogeneity across studies
is inevitable.
Finally, for our meta-analysis, we used absolute num-
bers (i.e. the number of people reporting multimorbidity
and sample sizes) to generate multimorbidity prevalence
estimates. However, this strategy did not take into account
the weights that were applied to the prevalence estimates in
some studies. Our results, therefore, need to be interpreted
with this caveat in mind.
Conclusion
Investigating multimorbidity prevalence is of great impor-
tance in the study of ageing. This systematic review of 70
studies reveals that a large proportion of the global popu-
lation, especially those above the age of 65, are affected by
multiple chronic diseases. The prevalence estimates of
multimorbidity differ among studies. The need for a con-
sistent operationalisation of multimorbidity is evident. It
will enable more accurate estimations of disease burden
and, consequently, more effective disease management and
resources distribution.
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